Sleep Apnea, ObstructiveNCT02832414
Effectiveness of an Intensive Weight Loss Program for Obstructive Sleep Apnea Syndrome (OSAS) Treatment.
A study testing Intensive weight loss program in people with Sleep Apnea, Obstructive and Obesity, run by Hospital Universitari de Bellvitge at 1 site in Spain.
Trial summary
The purpose of this study is to determine if a lifestyle change program for obese patients who are already receiving continuous positive airway pressure (CPAP) treatment can achieve weight loss and overall improvement of obstructive sleep apnea syndrome (OSAS). Read more about this study
- Who is it for?
- Ages 25 to 60 years
- Conditions the study is for
- Sleep Apnea, Obstructive, Obesity
- What is being tested?
- Intensive weight loss program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 42 participants
- Where
- 1 siteSpain
- Study dates
- Jul 2016to Jun 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patients who have been diagnosed with severe obstructive sleep apnea syndrome (AHI > 30) and are already receiving CPAP treatment (since at least 6 months), who have class I and class II obesity (body mass index (BMI) >= 30 kg /m2 y <= 40 kg/m2).
Who cannot join
- diseases that limit exercising or diet,
- cognitive impairment that prevents understanding the program,
- psychiatric disorders,
- severe diseases, major cardiovascular disease,
- clinical instability within the previous month,
- prior bariatric surgery,
- refusal to participate in the study,
- participation in another clinical trial.
Trial locations and contacts
1 site in 1 country.
Spain1 site
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona
About this study
The purpose of this study is to determine if a lifestyle change program for obese patients who are already receiving continuous positive airway pressure (CPAP) treatment can achieve weight loss and overall improvement of obstructive sleep apnea syndrome (OSAS).
Read the detailed description
Calculating the sample size:
The primary endpoint is the reduction of final apnea-hypopnea index (AHI) with respect to baseline. Assuming an alpha level of 0.05 and a bilateral approach to have 80% statistical power, the investigators estimate a final sample size of 42 patients is required to detect a 15 point difference in AHI between the intervention and control groups (clinically relevant difference), with a standard deviation of 15 (visit 9) and accounting for a 25% rate of attrition. Balanced groups are expected.
Lifestyle Change Program:
This will consist of a 3-month long first stage of intensive diet and progressive exercise with visits to a nutritionist every 15 days. A second stage will last until completion of one year, with a diet that is progressively higher in calories, more intense exercise, appointments that are spaced further apart and are alternatively individual and group visits.
Diet First stage: 12 weeks
- first 15 days: Very low calorie diet. A diet that is very low in calories will be started (600-800 kilocalories (Kcal), based on gender and level of physical activity) with low calorie shakes. Supplementing the diet with herbal teas and sugar-free beverages will be allowed.
- Up to week 12: 1200 Kcal diet with a low calorie shake replacing the evening meal. Exercising begins.
At each visit the nutritionist will provide advice on diet and lifestyle, with special emphasis on diet and exercise. Visits to the nutritionist will be every 15 days. The first two will be group visits and afterwards individual visits will alternate with group visits every 15 days (see chart below). On alternate weeks a nurse will phone the patients to remind them of the diet's basic guidelines.
Every session will last from 60 to 90 minutes and will be conducted by a nutritionist. The subjects will be asked to keep a 3 day log of what they eat at the start of the study and at and at each visit in order to estimate nutrient intake. Every patient will be provided with information about the entire program and the different group and individual sessions with the nutritionist. At each visit the participants will be weighed and asked for the results of the tests for ketones in the urine once a week. The nutritionist will follow compliance with the program and monitor for potential adverse events at each visit.
Second stage: from 12 weeks to 1 year A 1200-1500 Kcal diet will be maintained, based on gender and level of physical activity, without the low calorie shake. Calorie intake will be based on a Mediterranean diet, recommending a maximum fat intake of 30% and high consumption of fruit, vegetables, poultry, fish, lean meat and legumes, in accordance with the recommendations of the American Dietetic Association.
Visits to the nutritionist will take place monthly from the third to the sixth month and every 3 months from the sixth to the 12th month, with individual visits alternating with group visits (see chart below).
They will also receive a phone call every month, alternating with the visits, which will be made by the company that supplies the CPAP equipment.
Exercise
The following exercise program will be recommended:
- Walk briskly for at least 50-60 minutes at a time, at least 3 times per week, ideally 5 days a week. Exercising is to increase gradually, starting with 10 minute periods, repeated on the same day and that will be gradually increased as tolerated by the patient. Heart rate will be used to monitor exercise intensity, it is recommended that aerobic exercise be performed at 70-80% of maximum heart rate. (Lung (2014) 192:175-184).
- Every workout session will consist of stretching, 5-10' of warm up (50-60% of maximum heart rate (HR)), 40-50' of aerobic exercise performed at 70-80% of maximum HR and 5-10' of cool down (50-60% of maximum HR). The table for stretches to be performed before and after exercising will be given in writing. The patients will receive information on how to perform the exercises and everything related to it at a group training session before the start of the program.
- To encourage exercise, the chance to perform it at least once a week in guided groups, in the patient's town of residence, will be offered.
Follow up:
- On each visit to the nutritionist, in addition to data regarding adherence to the diet, data regarding adherence to the exercise program will be recorded: number of sessions and minutes/week.
- During the group sessions, the nurse in charge of the study will respond any questions that may arise concerning the development of the exercise program.
- Patients who have a smart phone will also be able to record their activity using an app (Endomondo) , which the nurse and the nutritionist will be able to access (see the section on variables). In addition to tracking their own exercise history, patients will be able to see that of the other patients in the study if they opt voluntarily to choose that option.
If any musculoskeletal complaints that are deemed relevant should occur during the course of the exercise program, the Rehabilitation Services will attend to the patients. The pain visual analogue scale (VAS) will be used for assessment. A VAS score equal to or greater than 4 (moderate pain) would require assessment to be made by the Rehabilitation Services.
Assessment of exercise capacity:
1 To measure the response to exercise an exercise tolerance test will be performed: the six minute walk test (6MWT), which will be evaluated using the reference values for obese individuals. It will be conducted before starting the program and at 3 and 12 months.
Sleep habits Subjects will be reminded of the need to sleep enough hours and of keeping a regular sleep schedule. Sleep hygiene guidelines will be provided in writing.
Control group: They will be managed according to the usual recommendations: they will be given a diet and exercise plan in writing, which is the one commonly used in the Dietetics Unit, established by the Dietetics Unit according to patient age and level of activity, without any other assessment or additional visits by the Dietetics Unit. Visits to the Sleep Disorders Unit will be scheduled to coincide with the assessments at 3 and 12 months, the same as for the intervention group.
Criteria for withdrawal from the study:
- occurrence of osteoarticular pain that prevents a patient from continuing to exercise
- a patient's continued refusal to follow the recommended guidelines
RECRUITMENT PERIOD: Potential candidates will be selected from among patients who are being followed by their doctor or nurse for CPAP treatment. All potential candidates will be invited to participate in the study in consecutive order until the required number of patients has been reached.
MONITORING PERIOD: All patients will complete the one year of monitoring. If any adverse effects occur during the monitoring period, they will be recorded and discontinuation of the protocol will be assessed. Diet-related adverse effects are not expected as the patients will be followed very closely by the nutritionist. In the event any exercise-related osteoarticular pain should occur, the Rehabilitation Services will assess the patients and determine whether the exercise should be modified or discontinued.
ETHICAL ISSUES: The study will be conducted in accordance with the principles of the Declaration of Helsinki, as well as of the Data Protection Act (Law 15/1999). All patients will be asked to provide informed consent, in accordance with the rules of the Ethics Committee at our institution.
Since all of the patients will be receiving CPAP treatment, there should be no ethical concerns about evaluating the effectiveness of an alternative treatment that in principle is less effective than CPAP, in patients with severe OSAS.
STATISTICAL ANALYSIS:
In order to evaluate the effectiveness of a change in lifestyle (diet and exercise) in obese patients with OSAS, the investigators will first perform a descriptive analysis of the demographic variables and baseline characteristics according to the number of cases and percentages for the qualitative variables and the investigators will use measures of central tendency (mean, median) and dispersion (standard deviation and interquartile range) for the quantitative variables.
In order to answer the primary and secondary objectives of this study, the investigators will run an inferential analysis comparing data at baseline, at 3 months and at one year in the two treatment groups. Tests for independent samples will be used in every case (between the control and experimental groups). Either the chi-square test or Fisher's exact test will be used, as appropriate, to compare categorical variables and Student's T-test will be used to compare continuous variables; if the variable under study does not meet the conditions for the applicability of parametric tests, a non-parametric alternative, the Mann Whitney U test, will be used.
An estimate of treatment effect in answer to the primary and secondary endpoints will be obtained from the confidence interval (95% CI) of the difference between means and percentages, as appropriate.
Efficacy assessment will be based on an analysis of the per protocol populations (PP) and intention-to-treat (ITT), with ITT the population being the main analysis. For the population analysis using ITT, the missing data will be filled in and sensitivity analysis will be conducted if more than one method of imputation is used. The PP population will be determined in accordance with compliance with visits as well as with the diet and exercise.
A safety assessment will be made by identifying the adverse effects that are considered to be most significant due to their frequency or severity.
In all cases the significance level used will be 5% (α=0.05) with a bilateral approach.
The statistical software that will be used for the analysis will be International Business Machines Corporation (IBM) Statistical Package for the Social Sciences (SPSS) Statistics 21.
- Conditions
- Sleep Apnea, Obstructive, Obesity
- Being tested
- Intensive weight loss program
- Medical subject headings
- Sleep Apnea, Obstructive, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intensive weight loss programBehavioural
behavioral and dietary supplement
| Study group | Role | What they receive |
|---|---|---|
| Regular program | No intervention | Not described |
| Intensive weight loss program | Active comparator | Not described Receives: Behavioral: Intensive weight loss program |
What is being measured
The primary outcome is the main question the study is designed to answer.
Improvement in the apnea-hypopnea index/hour: Sleep study: Standard polysomnography
Assess whether a lifestyle change program can be effective in the medium and long term for the treatment of OSAS in obese patients with OSAS who are already receiving CPAP treatment.
Measured: Baseline, at 3 months and 12 months.
Secondary outcomes (48)
waist circumference (above the upper iliac crest): centimetre
Measured: Baseline, at 3 months and 12 months.
neck circumfarence: centimetre
Measured: Baseline, at 3 months and 12 months.
waist to hip ratio
Measured: Baseline, at 3 months and 12 months.
Measurement of visceral fat (square centimetre) by an abdominal computerized tomography (CT) scan
Measured: Baseline, at 12 months.
Carotid intima-media (C-IMT) thickness (millimeter (mm)) by ultrasound of the supra-aortic vessels, using B-mode ultrasound
As a marker of subclinical cardiovascular disease
Measured: Baseline, at 3 months and 12 months.
Body fat composition by bioimpedance analysis (BIA 101, Akern Bioresearch, Florence, Italy).
Measured: Baseline, at 3 months and 12 months.
Measurement of health-related quality of life
Questionnaire regarding quality of life and sleep: Functional Outcomes of Sleep Questionnaire (FOSQ), Spanish language version (Ferrer et al Med Clin (Barc 1999; 113: 250-5).
Measured: Baseline, at 3 months and 12 months.
Measurement of health-related quality of life
Self-administered questionnaire regarding quality of life and sleep-related breathing disorders: Quebec Sleep Questionnaries (QSQ), Spanish language version (Lacasse et al Thorax 2004; 59: 494-9).
Measured: Baseline, at 3 months and 12 months.
Measurement of health-related quality of life
Euro quality of life (EuroQol) and the Analog pain scale for the assessment of well-being with regard to the disease under study. (Masa et al AJRCCM 2004 and Sleep and Breathing 2011).
Measured: Baseline, at 3 months and 12 months.
Age (years)
Measured: Baseline, at 3 months and 12 months.
Self-perceived sleepiness
It will be analyzed using the Epworth Sleepiness Scale (MW Johns, Sleep 1991, 14;540).
Measured: Baseline, at 3 months and 12 months.
Cardiovascular risk factors and comorbidity.
Using general medical history questionnaire
Measured: Baseline, at 3 months and 12 months.
OSAS-related symptoms
Measured: Baseline, at 3 months and 12 months.
Testing for ketones (milligram/deciliter) using test strips
Measured: Baseline, at 3 months and 12 months.
Record of physical activity: hours of exercise will be noted daily in a journal
Measured: Baseline, at 3 months and 12 months.
Exercise capacity: 6 minute walk test (6MWT)
Measured: Baseline, at 3 months and 12 months.
Pain: VAS Analog Scale for Pain
Measured: Baseline, at 3 months and 12 months.
Blood pressure
Measured: Baseline, at 3 months and 12 months.
CPAP compliance (mean hours of usage per night as recorded by the hour meters).
Measured: Baseline, at 3 months and 12 months.
CPAP related side effects
Measured: Baseline, at 3 months and 12 months.
Hours of sleep
Measured: Baseline, at 3 months and 12 months.
Fibrinogen (gram/liter)
Measured: Baseline, at 3 months and 12 months.
Glucose (millimole/liter)
Measured: Baseline, at 3 months and 12 months.
Markers of endothelial dysfunction: Asymetric Dimethylarginine (ADMA), intercellular adhesion molecule (ICAM-1), vascular endothelial cell adhesion molecule (VCAM-1), vascular endothelial growth factor (VEGF), endothelin
Measured: Baseline, at 3 months and 12 months.
Platelet activation and markers of the fibrinolytic system: p-selectin, Soluble CD40 ligand (sCD40), Plasminogen activator inhibitor (PAI-1)
Measured: Baseline, at 3 months and 12 months.
Markers of hemodynamic dysfunction: N-terminal pro brain natriuretic peptide (NT-proBNP)
Measured: Baseline, at 3 months and 12 months.
Markers of oxidative stress: isoprostanes
Measured: Baseline, at 3 months and 12 months.
Markers of inflammation: interleukin (IL) 6, IL-8, tumor necrosis factor (TNF) alpha and TNF soluble receptors 1 and 2, adiponectin
Measured: Baseline, at 3 months and 12 months.
Gender: male, female
Measured: Baseline
Weight (kilograme)
Measured: Baseline, at 3 months, and 12 months.
Height (meter)
Measured: Baseline, at 3 months, and 12 months.
Body mass index (BMI): dividing weight in kilograms by height in meters squared
Measured: Baseline, at 3 months, and 12 months.
Start of Obesity: period of obesity
Measured: Baseline
Adherence to diet monitoring by diet questionnaries
Measured: Baseline, at 3 months and 12 months
D-dimer (microgram/liter)
Measured: Baseline, at 3 months and 12 months
Prothrombin time (PT)
Measured: Baseline, at 3 months and 12 months
Activated partial thrombopastin time (APTT)
Measured: Baseline, at 3 months and 12 months
Triglycerides (millimole/liter)
Measured: Baseline, at 3 months and 12 months
Total cholesterol (millimole/liter)
Measured: Baseline, at 3 months and 12 months
Low density lipoprotein (LDL) cholesterol (millimole/liter)
Measured: Baseline, at 3 months and 12 months
High density lipoprotein (LDL) cholesterol (millimole/liter)
Measured: Baseline, at 3 months and 12 months
Uric acid (micromole/liter)
Measured: Baseline, at 3 months and 12 months
Creatinine (micromole/liter)
Measured: Baseline, at 3 months and 12 months
C-reactive protein (milligram/liter)
Measured: Baseline, at 3 months and 12 months
Aspartate aminotransferase (microgram/liter)
Measured: Baseline, at 3 months and 12 months
Alanine aminotransferase (microgram/liter)
Measured: Baseline, at 3 months and 12 months
Thyroid-Stimulating Hormone (TSH)
Measured: Baseline, at 3 months and 12 months
Glycosylated hemoglobin
Measured: Baseline, at 3 months and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2016 (estimated)
- Study startJul 2016
- Primary completionJun 2018
- Study completionJun 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Sleep Apnea, ObstructiveStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospital Universitari de Bellvitge
- Sponsor type
- University, hospital or other
- Collaborators
- Linde AG
- Responsible party
- Principal investigator, Carmen Monasterio, Hospital Universitari de Bellvitge
- Investigators
- Carmen Monasterio Ponsa, Doctor, Principal investigator, Hospital Universitari Bellvitge
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02832414
- Sponsor's protocol ID
- PR209/14
- Status last verified
- Aug 2019
- First submitted
- 6 Jul 2016
- Last updated
- 13 Aug 2019
- Results posted
- No
Publications
Lopez-Padros C, Salord N, Alves C, Vilarrasa N, Gasa M, Planas R, Montsserrat M, Virgili MN, Rodriguez C, Perez-Ramos S, Lopez-Cadena E, Ramos MI, Dorca J, Monasterio C. Effectiveness of an intensive weight-loss program for severe OSA in patients undergoing CPAP treatment: a randomized controlled trial. J Clin Sleep Med. 2020 Apr 15;16(4):503-514. doi: 10.5664/jcsm.8252.
PubMed 32003737
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of an Intensive Weight Loss Program for Obstructive Sleep Apnea Syndrome (OSAS) Treatment.
- ClinicalTrials.gov ID
- NCT02832414
- Acronym / sponsor ID
- PR209/14
- Conditions
- Sleep Apnea, Obstructive, Obesity
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- Hospital Universitari de BellvitgeUniversity, hospital or other
- Collaborators
- Linde AG
- Study start
- Jul 2016
- Primary completion
- Jun 2018 (actual)
- Study completion
- Jun 2018 (actual)
- First posted
- 14 Jul 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine if a lifestyle change program for obese patients who are already receiving continuous positive airway pressure (CPAP) treatment can achieve weight loss and overall improvement of obstructive sleep apnea syndrome (OSAS).
Detailed description
Calculating the sample size:
The primary endpoint is the reduction of final apnea-hypopnea index (AHI) with respect to baseline. Assuming an alpha level of 0.05 and a bilateral approach to have 80% statistical power, the investigators estimate a final sample size of 42 patients is required to detect a 15 point difference in AHI between the intervention and control groups (clinically relevant difference), with a standard deviation of 15 (visit 9) and accounting for a 25% rate of attrition. Balanced groups are expected.
Lifestyle Change Program:
This will consist of a 3-month long first stage of intensive diet and progressive exercise with visits to a nutritionist every 15 days. A second stage will last until completion of one year, with a diet that is progressively higher in calories, more intense exercise, appointments that are spaced further apart and are alternatively individual and group visits.
Diet First stage: 12 weeks
- first 15 days: Very low calorie diet. A diet that is very low in calories will be started (600-800 kilocalories (Kcal), based on gender and level of physical activity) with low calorie shakes. Supplementing the diet with herbal teas and sugar-free beverages will be allowed.
- Up to week 12: 1200 Kcal diet with a low calorie shake replacing the evening meal. Exercising begins.
At each visit the nutritionist will provide advice on diet and lifestyle, with special emphasis on diet and exercise. Visits to the nutritionist will be every 15 days. The first two will be group visits and afterwards individual visits will alternate with group visits every 15 days (see chart below). On alternate weeks a nurse will phone the patients to remind them of the diet's basic guidelines.
Every session will last from 60 to 90 minutes and will be conducted by a nutritionist. The subjects will be asked to keep a 3 day log of what they eat at the start of the study and at and at each visit in order to estimate nutrient intake. Every patient will be provided with information about the entire program and the different group and individual sessions with the nutritionist. At each visit the participants will be weighed and asked for the results of the tests for ketones in the urine once a week. The nutritionist will follow compliance with the program and monitor for potential adverse events at each visit.
Second stage: from 12 weeks to 1 year A 1200-1500 Kcal diet will be maintained, based on gender and level of physical activity, without the low calorie shake. Calorie intake will be based on a Mediterranean diet, recommending a maximum fat intake of 30% and high consumption of fruit, vegetables, poultry, fish, lean meat and legumes, in accordance with the recommendations of the American Dietetic Association.
Visits to the nutritionist will take place monthly from the third to the sixth month and every 3 months from the sixth to the 12th month, with individual visits alternating with group visits (see chart below).
They will also receive a phone call every month, alternating with the visits, which will be made by the company that supplies the CPAP equipment.
Exercise
The following exercise program will be recommended:
- Walk briskly for at least 50-60 minutes at a time, at least 3 times per week, ideally 5 days a week. Exercising is to increase gradually, starting with 10 minute periods, repeated on the same day and that will be gradually increased as tolerated by the patient. Heart rate will be used to monitor exercise intensity, it is recommended that aerobic exercise be performed at 70-80% of maximum heart rate. (Lung (2014) 192:175-184).
- Every workout session will consist of stretching, 5-10' of warm up (50-60% of maximum heart rate (HR)), 40-50' of aerobic exercise performed at 70-80% of maximum HR and 5-10' of cool down (50-60% of maximum HR). The table for stretches to be performed before and after exercising will be given in writing. The patients will receive information on how to perform the exercises and everything related to it at a group training session before the start of the program.
- To encourage exercise, the chance to perform it at least once a week in guided groups, in the patient's town of residence, will be offered.
Follow up:
- On each visit to the nutritionist, in addition to data regarding adherence to the diet, data regarding adherence to the exercise program will be recorded: number of sessions and minutes/week.
- During the group sessions, the nurse in charge of the study will respond any questions that may arise concerning the development of the exercise program.
- Patients who have a smart phone will also be able to record their activity using an app (Endomondo) , which the nurse and the nutritionist will be able to access (see the section on variables). In addition to tracking their own exercise history, patients will be able to see that of the other patients in the study if they opt voluntarily to choose that option.
If any musculoskeletal complaints that are deemed relevant should occur during the course of the exercise program, the Rehabilitation Services will attend to the patients. The pain visual analogue scale (VAS) will be used for assessment. A VAS score equal to or greater than 4 (moderate pain) would require assessment to be made by the Rehabilitation Services.
Assessment of exercise capacity:
1 To measure the response to exercise an exercise tolerance test will be performed: the six minute walk test (6MWT), which will be evaluated using the reference values for obese individuals. It will be conducted before starting the program and at 3 and 12 months.
Sleep habits Subjects will be reminded of the need to sleep enough hours and of keeping a regular sleep schedule. Sleep hygiene guidelines will be provided in writing.
Control group: They will be managed according to the usual recommendations: they will be given a diet and exercise plan in writing, which is the one commonly used in the Dietetics Unit, established by the Dietetics Unit according to patient age and level of activity, without any other assessment or additional visits by the Dietetics Unit. Visits to the Sleep Disorders Unit will be scheduled to coincide with the assessments at 3 and 12 months, the same as for the intervention group.
Criteria for withdrawal from the study:
- occurrence of osteoarticular pain that prevents a patient from continuing to exercise
- a patient's continued refusal to follow the recommended guidelines
RECRUITMENT PERIOD: Potential candidates will be selected from among patients who are being followed by their doctor or nurse for CPAP treatment. All potential candidates will be invited to participate in the study in consecutive order until the required number of patients has been reached.
MONITORING PERIOD: All patients will complete the one year of monitoring. If any adverse effects occur during the monitoring period, they will be recorded and discontinuation of the protocol will be assessed. Diet-related adverse effects are not expected as the patients will be followed very closely by the nutritionist. In the event any exercise-related osteoarticular pain should occur, the Rehabilitation Services will assess the patients and determine whether the exercise should be modified or discontinued.
ETHICAL ISSUES: The study will be conducted in accordance with the principles of the Declaration of Helsinki, as well as of the Data Protection Act (Law 15/1999). All patients will be asked to provide informed consent, in accordance with the rules of the Ethics Committee at our institution.
Since all of the patients will be receiving CPAP treatment, there should be no ethical concerns about evaluating the effectiveness of an alternative treatment that in principle is less effective than CPAP, in patients with severe OSAS.
STATISTICAL ANALYSIS:
In order to evaluate the effectiveness of a change in lifestyle (diet and exercise) in obese patients with OSAS, the investigators will first perform a descriptive analysis of the demographic variables and baseline characteristics according to the number of cases and percentages for the qualitative variables and the investigators will use measures of central tendency (mean, median) and dispersion (standard deviation and interquartile range) for the quantitative variables.
In order to answer the primary and secondary objectives of this study, the investigators will run an inferential analysis comparing data at baseline, at 3 months and at one year in the two treatment groups. Tests for independent samples will be used in every case (between the control and experimental groups). Either the chi-square test or Fisher's exact test will be used, as appropriate, to compare categorical variables and Student's T-test will be used to compare continuous variables; if the variable under study does not meet the conditions for the applicability of parametric tests, a non-parametric alternative, the Mann Whitney U test, will be used.
An estimate of treatment effect in answer to the primary and secondary endpoints will be obtained from the confidence interval (95% CI) of the difference between means and percentages, as appropriate.
Efficacy assessment will be based on an analysis of the per protocol populations (PP) and intention-to-treat (ITT), with ITT the population being the main analysis. For the population analysis using ITT, the missing data will be filled in and sensitivity analysis will be conducted if more than one method of imputation is used. The PP population will be determined in accordance with compliance with visits as well as with the diet and exercise.
A safety assessment will be made by identifying the adverse effects that are considered to be most significant due to their frequency or severity.
In all cases the significance level used will be 5% (α=0.05) with a bilateral approach.
The statistical software that will be used for the analysis will be International Business Machines Corporation (IBM) Statistical Package for the Social Sciences (SPSS) Statistics 21.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Regular program | No intervention | – |
| Intensive weight loss program | Active comparator | Behavioral: Intensive weight loss program |
Who may qualify
- Ages
- 25 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Patients who have been diagnosed with severe obstructive sleep apnea syndrome (AHI > 30) and are already receiving CPAP treatment (since at least 6 months), who have class I and class II obesity (body mass index (BMI) >= 30 kg /m2 y <= 40 kg/m2).
Key exclusion criteria (8 listed)
- diseases that limit exercising or diet,
- cognitive impairment that prevents understanding the program,
- psychiatric disorders,
- severe diseases, major cardiovascular disease,
- clinical instability within the previous month,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intensive weight loss programbehavioral and dietary supplement | Behavioural | Intensive weight loss program |
Primary outcome
Improvement in the apnea-hypopnea index/hour: Sleep study: Standard polysomnography
Time frame: Baseline, at 3 months and 12 months.
Assess whether a lifestyle change program can be effective in the medium and long term for the treatment of OSAS in obese patients with OSAS who are already receiving CPAP treatment.
48 secondary outcomes
waist circumference (above the upper iliac crest): centimetre
Time frame: Baseline, at 3 months and 12 months.
neck circumfarence: centimetre
Time frame: Baseline, at 3 months and 12 months.
waist to hip ratio
Time frame: Baseline, at 3 months and 12 months.
Measurement of visceral fat (square centimetre) by an abdominal computerized tomography (CT) scan
Time frame: Baseline, at 12 months.
Carotid intima-media (C-IMT) thickness (millimeter (mm)) by ultrasound of the supra-aortic vessels, using B-mode ultrasound
Time frame: Baseline, at 3 months and 12 months.
Body fat composition by bioimpedance analysis (BIA 101, Akern Bioresearch, Florence, Italy).
Time frame: Baseline, at 3 months and 12 months.
Measurement of health-related quality of life
Time frame: Baseline, at 3 months and 12 months.
Measurement of health-related quality of life
Time frame: Baseline, at 3 months and 12 months.
Measurement of health-related quality of life
Time frame: Baseline, at 3 months and 12 months.
Age (years)
Time frame: Baseline, at 3 months and 12 months.
Self-perceived sleepiness
Time frame: Baseline, at 3 months and 12 months.
Cardiovascular risk factors and comorbidity.
Time frame: Baseline, at 3 months and 12 months.
OSAS-related symptoms
Time frame: Baseline, at 3 months and 12 months.
Testing for ketones (milligram/deciliter) using test strips
Time frame: Baseline, at 3 months and 12 months.
Record of physical activity: hours of exercise will be noted daily in a journal
Time frame: Baseline, at 3 months and 12 months.
Exercise capacity: 6 minute walk test (6MWT)
Time frame: Baseline, at 3 months and 12 months.
Pain: VAS Analog Scale for Pain
Time frame: Baseline, at 3 months and 12 months.
Blood pressure
Time frame: Baseline, at 3 months and 12 months.
CPAP compliance (mean hours of usage per night as recorded by the hour meters).
Time frame: Baseline, at 3 months and 12 months.
CPAP related side effects
Time frame: Baseline, at 3 months and 12 months.
Hours of sleep
Time frame: Baseline, at 3 months and 12 months.
Fibrinogen (gram/liter)
Time frame: Baseline, at 3 months and 12 months.
Glucose (millimole/liter)
Time frame: Baseline, at 3 months and 12 months.
Markers of endothelial dysfunction: Asymetric Dimethylarginine (ADMA), intercellular adhesion molecule (ICAM-1), vascular endothelial cell adhesion molecule (VCAM-1), vascular endothelial growth factor (VEGF), endothelin
Time frame: Baseline, at 3 months and 12 months.
Platelet activation and markers of the fibrinolytic system: p-selectin, Soluble CD40 ligand (sCD40), Plasminogen activator inhibitor (PAI-1)
Time frame: Baseline, at 3 months and 12 months.
Markers of hemodynamic dysfunction: N-terminal pro brain natriuretic peptide (NT-proBNP)
Time frame: Baseline, at 3 months and 12 months.
Markers of oxidative stress: isoprostanes
Time frame: Baseline, at 3 months and 12 months.
Markers of inflammation: interleukin (IL) 6, IL-8, tumor necrosis factor (TNF) alpha and TNF soluble receptors 1 and 2, adiponectin
Time frame: Baseline, at 3 months and 12 months.
Gender: male, female
Time frame: Baseline
Weight (kilograme)
Time frame: Baseline, at 3 months, and 12 months.
Height (meter)
Time frame: Baseline, at 3 months, and 12 months.
Body mass index (BMI): dividing weight in kilograms by height in meters squared
Time frame: Baseline, at 3 months, and 12 months.
Start of Obesity: period of obesity
Time frame: Baseline
Adherence to diet monitoring by diet questionnaries
Time frame: Baseline, at 3 months and 12 months
D-dimer (microgram/liter)
Time frame: Baseline, at 3 months and 12 months
Prothrombin time (PT)
Time frame: Baseline, at 3 months and 12 months
Activated partial thrombopastin time (APTT)
Time frame: Baseline, at 3 months and 12 months
Triglycerides (millimole/liter)
Time frame: Baseline, at 3 months and 12 months
Total cholesterol (millimole/liter)
Time frame: Baseline, at 3 months and 12 months
Low density lipoprotein (LDL) cholesterol (millimole/liter)
Time frame: Baseline, at 3 months and 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2019.
- Derived from this study: PubMed 32003737Lopez-Padros C, Salord N, Alves C, Vilarrasa N, Gasa M, Planas R, Montsserrat M, Virgili MN, Rodriguez C, Perez-Ramos S, Lopez-Cadena E, Ramos MI, Dorca J, Monasterio C. Effectiveness of an intensive weight-loss program for severe OSA in patients undergoing CPAP treatment: a randomized controlled trial. J Clin Sleep Med. 2020 Apr 15;16(4):503-514. doi: 10.5664/jcsm.8252.
Related trials for Sleep Apnea, Obstructive
RecruitingObservational study
Development and Clinical Validation of Artificial Intelligence Algorithms for Sleep Staging and Obstructive Sleep Apnea Screening Based on a Large-Scale Model Trained on Multimodal Physiological Signals From Diverse Populations
Sleep Apnea, Obstructive, Sleep Staging
RecruitingObservational study
Development of a Wearable Point of Care Monitoring Device for Pediatric Obstructive Sleep Apnea
Pediatric Obstructive Sleep Apnea
Not yet recruiting
Effect of High-flow Nasal Cannula Oxygenation on the Incidence of Hypoxemia During Painless Gastrointestinal Endoscopy in Patients at High Risk for Obstructive Sleep Apnea Syndrome in High-altitude Regions
Hypoxemia, Gastric Cancer (Diagnosis)
Not yet recruitingPhase 2
Oxytocin for Respiratory Compromise and Hypoventilation Induced by Drugs
Obesity & Overweight, Respiratory Depression
Enrolling by invitation
Myofunctional Therapy for Obstructive Sleep Apnea
Obstructive Sleep Apnea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Carmen Monasterio Ponsa, Doctor principal investigator
Hospital Universitari Bellvitge
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Intensive weight loss program in people with Sleep Apnea, Obstructive and Obesity, run by Hospital Universitari de Bellvitge at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improvement in the apnea-hypopnea index/hour: Sleep study: Standard polysomnography (time frame: Baseline, at 3 months and 12 months.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02832414, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2019.